Status:
RECRUITING
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Lead Sponsor:
King's College London
Collaborating Sponsors:
Guy's and St Thomas' NHS Foundation Trust
Action Medical Research
Conditions:
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Autoimmune Encephalitis
Eligibility:
All Genders
8-24 years
Brief Summary
Autoimmune encephalitis is brain inflammation caused by the immune system mistakenly reacting against proteins in the brain. The commonest form is called NMDAR-antibody encephalitis (N-methyl-D-aspart...
Detailed Description
This study aims to develop non-invasive, in vivo measures of neurobiological dysfunction derived from the overarching hypothesis that dysfunction of inhibitory interneurons alters the cerebral concent...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- NMDAR-antibody encephalitis group:
- Age 8-24 years at study enrollment.
- Disease onset in the last 12 months before study enrollment.
- Meets consensus diagnostic criteria (Graus et al., 2016) for either probable anti-NMDAR encephalitis OR definite anti-NMDAR encephalitis.
- Antibody-negative autoimmune encephalitis group:
- Age 8-24 years at study enrollment.
- Disease onset in the last 12 months before study enrollment.
- Meets consensus diagnostic criteria (Graus et al., 2016) for either autoantibody-negative but probable autoimmune encephalitis OR definite autoimmune limbic encephalitis.
- Healthy control group:
- 1\. Age 8-24 years at study enrollment.
- EXCLUSION CRITERIA:
- All participants:
- 1\. Any clear contra-indication for an MRI scan. In particular this would be due to the presence of any implanted devices or metal from previous surgery or accident.
- Healthy control group:
- 1\. A known neurological or neurodevelopmental disorder.
- NMDAR-antibody encephalitis and antibody-negative autoimmune encephalitis groups:
- Alternative more likely cause of neurological symptoms than autoimmune encephalitis, i.e. reasonable exclusion of other diagnoses as per consensus criteria (Graus et al., 2016).
- Severe movement disorder/uncontrolled epilepsy/dysautonomia.
- Previous infective encephalitis with major destructive brain lesions.
Exclusion
Key Trial Info
Start Date :
May 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05280600
Start Date
May 19 2022
End Date
February 28 2026
Last Update
October 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guy's and St Thomas' NHS Foundation Trust
London, Greater London, United Kingdom, SE1 7EH